Overview

Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor

Status:
Completed

Trial end date:
2017-09-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving imatinib mesylate after surgery may kill any remaining tumor cells. It is not yet known whether imatinib mesylate is more effective than observation only in treating gastrointestinal stromal tumor. PURPOSE: This randomized phase III trial is studying imatinib mesylate to see how well it works compared to observation only in treating patients who have undergone surgery for localized gastrointestinal stromal tumor.

Phase:

Phase 3

Details

Lead Sponsor:

European Organisation for Research and Treatment of Cancer - EORTC

Collaborators:

Grupo Espanol de Investigacion en Sarcomas
Italian Sarcoma Group
UNICANCER

Treatments:

Imatinib Mesylate